USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients

Gastric cancer (GC) is one of the most frequent gastrointestinal malignancies in the world. WNT signaling pathway has a key role in the occurrence and progression of GC. USP6NL belongs to the GAP protein family that regulates the WNT signaling by the β-catenin stabilization during tumor progression....

Full description

Saved in:
Bibliographic Details
Main Authors: Zahra Basirat, Negin Taghehchian, Mohammad Reza Abbaszadegan, Meysam Moghbeli
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225001133
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849233552410935296
author Zahra Basirat
Negin Taghehchian
Mohammad Reza Abbaszadegan
Meysam Moghbeli
author_facet Zahra Basirat
Negin Taghehchian
Mohammad Reza Abbaszadegan
Meysam Moghbeli
author_sort Zahra Basirat
collection DOAJ
description Gastric cancer (GC) is one of the most frequent gastrointestinal malignancies in the world. WNT signaling pathway has a key role in the occurrence and progression of GC. USP6NL belongs to the GAP protein family that regulates the WNT signaling by the β-catenin stabilization during tumor progression. Therefore, for the first time in the present study, we examined the role of USP6NL in tumor progression through the regulation of WNT signaling pathway among GC patients. C-MYC and MSX2 were also assessed in GC patients as the WNT target genes to evaluate the role of USP6NL during GC progression via WNT regulation. Eighty-three freshly tumor and corresponding normal tissues were enrolled to assess the levels of USP6NL, MSX2, and C-MYC mRNA expressions using the Real time polymerase chain reaction. There was significant higher levels of USP6NL in non-cardia compared with cardia tumors (p = 0.03). There was also significant higher levels of USP6NL expressions in non-cardia tumors of females compared with males (p = 0.032). Low-grade tumors with MSX2 up regulation were significantly associated with low survival (p = 0.012). MSX2 up regulation was significantly correlated with lower survival among the female GC patients (p = 0.041). The levels of USP6NL was also significantly correlated with the levels of MSX2 (p ≤ 0.0001) and C-MYC (p = 0.001). USP6NL/MSX2/C-MYC axis can be introduced as a reliable diagnostic marker or therapeutic target in GC following the further in-vitro and animal studies.
format Article
id doaj-art-84960d76ff264f88bd2e86a912848116
institution Kabale University
issn 2468-2942
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Cancer Treatment and Research Communications
spelling doaj-art-84960d76ff264f88bd2e86a9128481162025-08-20T05:07:20ZengElsevierCancer Treatment and Research Communications2468-29422025-01-014410097710.1016/j.ctarc.2025.100977USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patientsZahra Basirat0Negin Taghehchian1Mohammad Reza Abbaszadegan2Meysam Moghbeli3Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, IranMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, IranMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, IranCorresponding author.; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, IranGastric cancer (GC) is one of the most frequent gastrointestinal malignancies in the world. WNT signaling pathway has a key role in the occurrence and progression of GC. USP6NL belongs to the GAP protein family that regulates the WNT signaling by the β-catenin stabilization during tumor progression. Therefore, for the first time in the present study, we examined the role of USP6NL in tumor progression through the regulation of WNT signaling pathway among GC patients. C-MYC and MSX2 were also assessed in GC patients as the WNT target genes to evaluate the role of USP6NL during GC progression via WNT regulation. Eighty-three freshly tumor and corresponding normal tissues were enrolled to assess the levels of USP6NL, MSX2, and C-MYC mRNA expressions using the Real time polymerase chain reaction. There was significant higher levels of USP6NL in non-cardia compared with cardia tumors (p = 0.03). There was also significant higher levels of USP6NL expressions in non-cardia tumors of females compared with males (p = 0.032). Low-grade tumors with MSX2 up regulation were significantly associated with low survival (p = 0.012). MSX2 up regulation was significantly correlated with lower survival among the female GC patients (p = 0.041). The levels of USP6NL was also significantly correlated with the levels of MSX2 (p ≤ 0.0001) and C-MYC (p = 0.001). USP6NL/MSX2/C-MYC axis can be introduced as a reliable diagnostic marker or therapeutic target in GC following the further in-vitro and animal studies.http://www.sciencedirect.com/science/article/pii/S2468294225001133Gastric cancerUSP6NLMSX2C-MYCWNT signaling
spellingShingle Zahra Basirat
Negin Taghehchian
Mohammad Reza Abbaszadegan
Meysam Moghbeli
USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients
Cancer Treatment and Research Communications
Gastric cancer
USP6NL
MSX2
C-MYC
WNT signaling
title USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients
title_full USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients
title_fullStr USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients
title_full_unstemmed USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients
title_short USP6NL and MSX2 as the novel diagnostic markers in gastric cancer patients
title_sort usp6nl and msx2 as the novel diagnostic markers in gastric cancer patients
topic Gastric cancer
USP6NL
MSX2
C-MYC
WNT signaling
url http://www.sciencedirect.com/science/article/pii/S2468294225001133
work_keys_str_mv AT zahrabasirat usp6nlandmsx2asthenoveldiagnosticmarkersingastriccancerpatients
AT negintaghehchian usp6nlandmsx2asthenoveldiagnosticmarkersingastriccancerpatients
AT mohammadrezaabbaszadegan usp6nlandmsx2asthenoveldiagnosticmarkersingastriccancerpatients
AT meysammoghbeli usp6nlandmsx2asthenoveldiagnosticmarkersingastriccancerpatients